SARS1

Chr 1AR

seryl-tRNA synthetase 1

Also known as: NEDMAS, SARS, SERRS, SERS

The encoded enzyme catalyzes the transfer of L-serine to tRNA(Ser), a critical step in protein synthesis. Biallelic mutations cause neurodevelopmental disorder with microcephaly, ataxia, and seizures, inherited in an autosomal recessive pattern. The gene is highly constrained against loss-of-function variation in the general population.

OMIMResearchSummary from RefSeq, OMIM
DNmechanismARLOEUF 0.211 OMIM phenotype
Clinical SummarySARS1
🧬
Gene-Disease Validity (ClinGen)
neurodevelopmental disorder with microcephaly, ataxia, and seizures · ARLimited

Limited evidence — not for standalone diagnostic reporting

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint
0.21LOEUF
pLI 0.999
Z-score 4.70
OE 0.07 (0.030.21)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint
2.66Z-score
OE missense 0.57 (0.500.65)
170 obs / 299.4 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios
LoF OE0.07 (0.030.21)
00.351.4
Missense OE0.57 (0.500.65)
00.61.4
Synonymous OE0.82
01.21.6
LoF obs/exp: 2 / 29.6Missense obs/exp: 170 / 299.4Syn Z: 1.48
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
limitedSARS1-related neurodevelopmental disorderDNAD
moderateSARS1-related neurodevelopmental disorder with microcephaly, ataxia, and seizuresOTHERAR
DN
0.4983th %ile
GOF
0.4480th %ile
LOF
0.4726th %ile

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and dominant-negative). The Badonyi & Marsh model scores dominant-negative highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports loss-of-function (haploinsufficiency). Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFLOEUF 0.21
DN1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNComplementation assays in S. cerevisiae and serylation assays in both yeast strains and patient fibroblasts proved a loss-of-function, dominant negative effect.PMID:36041817

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

SARS1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC